ESMO Breast 2024 | Second-line fulvestrant in pretreated metastatic invasive lobular carcinoma

Jason Mouabbi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the efficacy of second-line fulvestrant in patients with metastatic invasive lobular carcinoma (mILC) following treatment with aromatase inhibitors (AI) and CDK4/6 inhibitors, based on an observational study. Fulvestrant was found to be ineffective, and no patients assessed continued on fulvestrant after a year. These findings highlight the need for new therapeutic strategies in pre-treated mILC. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.